WeWork Companies LLC Commends Franchisee WeWork India on IPO and Public Listing
14.10.2025 16:00:00 CEST | Business Wire | Press Release
WeWork Companies LLC (WeWork), the privately held parent company of its franchisee WeWork India Management Limited (“WeWork India”), applauds and fully supports the launch of their IPO and listing on the National Stock Exchange of India. The entities have enjoyed a long and positive partnership since WeWork India’s founding in 2017, during which time it has grown to become the top flexible office space provider in the country.
“WeWork India is shaping the future of work in India,” said John Santora, Chief Executive Officer of WeWork. “The listing marks an important moment for the country’s flexible workspace sector, underscoring both market confidence and growing demand for dynamic office solutions in the region. We have been a proud partner of WeWork India and have witnessed their rise as the clear leader in the space in which they operate.”
“Over the last eight years, our partnership with WeWork has remained a strong pillar of our growth and innovation journey in India. As a globally trusted brand with a strong international network, WeWork brings operational excellence that resonates with global enterprises as well as high-growth companies. Their continued support and alignment with our vision has enabled us to build a resilient, future-ready business. This has allowed us to deliver premium, flexible workspace solutions tailored to evolving business needs, while consistently creating long-term value for our members and stakeholders. Our IPO marks a key milestone in this journey and underscores the strength of our partnership and the strategic alignment between both teams,” added Karan Virwani, Managing Director & CEO, WeWork India.
As corporate occupiers look to rebalance their real estate portfolios towards a higher mix of flexible office space globally, both entities have seen substantial operating momentum in 2025 and are well-positioned for continued growth.
Today, WeWork operates 45 million square feet of office space in 37 countries. In 2025, their global occupancy grew from 70% to 77%, surpassing 90% in many markets including Toronto, Silicon Valley, Houston, Nashville, Milan, Madrid, UAE, Kuala Lumpur, and Jakarta.
WeWork India operates 7.67 million square feet of office space in India, and has demonstrated strong growth, profitability, and resilience. With market-leading scale in prime locations across major Indian cities, a diversified client base including Fortune 500 companies, and a vision for community-driven workspaces, WeWork India is poised to benefit from the surging demand for agile office solutions among corporate occupiers.
WeWork India’s IPO is a milestone that reinforces WeWork’s position as the leading global brand for flexible office space, further evidenced by their sustained profitability, strengthened balance sheet, and renewed momentum across all markets. Following the listing, WeWork will remain a supportive partner and minority shareholder of WeWork India. WeWork itself will continue as a privately held company with no debt, substantial liquidity, and no plans for a public listing.
About WeWork:
WeWork is a leading global real estate platform, purpose-built to empower businesses of all sizes with flexible workplace solutions, hospitality-driven experiences, best-in-class services, and innovative technology. With a curated portfolio of over 600 thoughtfully designed locations, spanning 45M square feet worldwide, WeWork helps more than half a million members — from emerging startups to Fortune 100 companies – perform their best work, today and tomorrow.
To learn more, visit wework.com.
About WeWork India:
Launched in 2017, WeWork India is one of India's leading premium flexible workspace operators - GPTW certified (Nov 2024 – Nov 2025). WeWork India is the largest operator by total revenue for the past three fiscal years*. Since its inception, WeWork India has expanded across 8 cities in Chennai, New Delhi, Gurugram, Noida, Mumbai, Bengaluru, Pune, and Hyderabad, with 68 operational centres spanning 7.67 million square feet (as of June 2025). WeWork India has played a significant role in the growth of the flexible workspace sector and contributed to the evolution of its products and services, providing customised and curated solutions for various office space needs*. [*Source: CBRE]
View source version on businesswire.com: https://www.businesswire.com/news/home/20251014787630/en/
Contacts
Media contact: press@wework.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom